Atossa Therapeutics (ATOS) AI Stock Analysis

• Market Cap: $45.55M
• Dividend Yield: N/A
• Average Volume (3M): 1.16M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.12
• Revenue Growth: N/A
• EPS Growth: -9.42%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.05
• Shares Outstanding: 8,611,428
• 10 Day Avg. Volume: 1,949,046
• 30 Day Avg. Volume: 1,157,820
• PEG Ratio: 4.19
• Price to Book (P/B): 24.93
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -84.67
• Enterprise Value/Market Cap: -0.13
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 371.64
• Enterprise Value/Ebitda: 0.18
• 1Y Price Target: $6.33
• Price Target Upside: 19.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $5.50 ▲(3.97% Upside)

The score is held down primarily by weak financial performance (no revenue, ongoing losses, and rising TTM cash burn) and a strongly bearish technical setup (price far below key moving averages with negative MACD). Positive FDA-related corporate milestones provide some support, but valuation is difficult to justify with negative earnings and no dividend.

Positive Factors

Zero debt balance sheet

A zero-debt capital structure materially lowers financial risk for a cash-burning clinical-stage biotech. Over the next several months it preserves flexibility to structure non-dilutive funding, access debt if needed, or prioritize strategic partnerships without immediate lender constraints.

FDA 'Study May Proceed' clearance

Regulatory clearance to initiate a metastatic ER+/HER2- trial is a structural de-risking event: it enables execution of a pivotal clinical program, generates prospective clinical data, and materially advances the pathway toward approval or partnering opportunities over the coming 2-6 months.

Orphan drug designation for DMD

Orphan designation provides regulatory incentives and potential marketing exclusivity that strengthen long-term commercial and partnership economics. This structural benefit improves the program’s attractiveness to collaborators and can materially raise the expected value of a successful DMD indication.

Negative Factors

Pre-revenue with persistent operating losses

As a pre-revenue clinical-stage company, lack of product sales means continued reliance on financing to fund R&D. Persistent multi‑million operating losses limit runway, amplify execution risk, and mean business viability depends on future trial success or sustained capital access over the next several months.

Shrinking shareholders' equity and negative ROE

Material erosion of equity and persistently negative returns on capital signal dilution and capital inefficiency. Over a medium-term horizon this constrains financing options, weakens the balance sheet buffer for clinical setbacks, and raises the probability of dilutive capital raises.

Weak cash generation; elevated cash burn

Sustained negative operating cash flow implies the company must raise capital to sustain trials and operations. Elevated burn increases dilution risk and can force prioritization of a single program or milestone-driven strategy, reducing optionality and stressing long-term R&D plans.

Atossa Therapeutics Business Overview & Revenue Model

Company Description

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

How the Company Makes Money

Atossa Therapeutics primarily generates revenue through strategic partnerships and collaborations with other pharmaceutical companies, licensing agreements, and potential milestone payments related to the development and commercialization of its drug candidates. As a clinical-stage company, revenue is also contingent upon successful clinical trial results and subsequent regulatory approvals. Additionally, Atossa may engage in fundraising activities to support its ongoing research and development efforts.

Atossa Therapeutics Financial Statement Overview

Summary

Development-stage profile with zero revenue, persistent net losses, and worsening TTM cash burn (operating cash flow -$26.3M). A key offset is a zero-debt balance sheet, but shrinking equity and negative ROE highlight ongoing funding and dilution risk.

Income Statement

Results remain pre-revenue (total revenue is 0 across annual periods and TTM (Trailing-Twelve-Months)), with persistent operating losses. Losses are sizable and have not meaningfully improved: net loss was -$25.5M in 2024 and -$30.2M in TTM (Trailing-Twelve-Months), indicating continued heavy R&D/operating spend relative to the current revenue base. While annual net loss narrowed versus 2023 (-$30.1M), the latest TTM (Trailing-Twelve-Months) shows deterioration again, highlighting volatility and limited earnings visibility.

Balance Sheet

The balance sheet is conservatively levered with zero total debt in recent years (and minimal debt in 2020), which lowers financial risk and supports funding flexibility. However, equity has been shrinking meaningfully over time (stockholders’ equity fell from ~$138.1M in 2021 to ~$71.5M in 2024 and ~$49.8M in TTM (Trailing-Twelve-Months)), consistent with ongoing losses and cash burn. Returns on equity are negative across the period (e.g., -35.7% in 2024; -42.8% in TTM), underscoring that capital is not currently generating profits.

Cash Flow

Cash generation remains weak with consistently negative operating cash flow and free cash flow, reflecting a business still in investment/burn mode. Operating cash flow was -$21.0M in 2024 and worsened to -$26.3M in TTM (Trailing-Twelve-Months), implying an elevated ongoing cash need. A positive note is that free cash flow broadly tracks net losses (free cash flow to net income ~1.0), suggesting limited non-cash earnings distortion, but the overall trajectory still points to sustained cash consumption and potential future funding requirements.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-16.00K	-17.00K	-23.00K	-8.00K	-23.00K	-46.60K
EBITDA	-32.28M	-27.60M	-31.35M	-27.68M	-20.50M	-14.56M
Net Income	-30.18M	-25.50M	-30.09M	-26.96M	-20.61M	-17.83M
Balance Sheet
Total Assets	58.01M	76.44M	96.25M	123.53M	141.26M	42.84M
Cash, Cash Equivalents and Short-Term Investments	51.84M	71.08M	88.46M	110.89M	136.38M	39.66M
Total Debt	0.00	0.00	0.00	0.00	0.00	18.05K
Total Liabilities	8.22M	4.97M	5.24M	5.57M	3.13M	15.68M
Stockholders Equity	49.79M	71.48M	91.02M	117.96M	138.14M	27.17M
Cash Flow
Free Cash Flow	-26.29M	-21.05M	-20.95M	-20.79M	-16.48M	-11.58M
Operating Cash Flow	-26.27M	-21.03M	-20.94M	-20.76M	-16.47M	-11.57M
Investing Cash Flow	-16.00K	-19.00K	-14.00K	-4.73M	-9.00K	-9.37K
Financing Cash Flow	3.37M	3.67M	-1.48M	0.00	113.30M	38.55M

Atossa Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.29
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATOS, the sentiment is Negative. The current price of 5.29 is below the 20-day moving average (MA) of 8.62, below the 50-day MA of 9.98, and below the 200-day MA of 12.10, indicating a bearish trend. The MACD of -1.15 indicates Positive momentum. The RSI at 23.26 is Positive, neither overbought nor oversold. The STOCH value of 7.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATOS.

Atossa Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SEER	54 Neutral	$100.98M	-1.28	-25.74%	―	13.77%	-4.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INO	47 Neutral	$114.73M	-0.60	-328.45%	―	-10.36%	42.36%
OVID	47 Neutral	$192.67M	―	-60.06%	―	946.61%	-11.30%
AGEN	45 Neutral	$98.28M	-1.30	―	―	-33.41%	81.19%
ATOS	43 Neutral	$45.55M	-1.51	-48.89%	―	―	-9.42%
TVGN	41 Neutral	$56.51M	-1.58	―	―	―	-234.46%

Atossa Therapeutics Corporate Events

Atossa Therapeutics Sets 15-for-1 Reverse Stock Split

On December 19, 2025, Atossa Therapeutics stockholders approved an amendment to the company’s Certificate of Incorporation authorizing a reverse stock split of its common stock at a ratio between 5:1 and 20:1, with 33.7 million votes in favor, 27.9 million against and a small number of abstentions. Following this approval, the board of directors set a 15:1 reverse stock split to take effect at 12:01 a.m. Eastern Time on February 2, 2026, after which every 15 existing shares will be automatically combined into one new share, the stock will begin trading on a split-adjusted basis under a new CUSIP while retaining the ATOS ticker, fractional shares will be cashed out based on the January 30, 2026 closing price, and proportional adjustments will be made to equity awards, share reserves and preferred stock conversion terms, effectively reducing the share count and consolidating the company’s capital structure for existing shareholders.

The most recent analyst rating on (ATOS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Atossa Therapeutics stock, see the ATOS Stock Forecast page.

Atossa Therapeutics outlines strategy for lead (Z)-Endoxifen program

In a recent Form 8-K, Atossa Therapeutics furnished a corporate presentation outlining its development and regulatory strategy for its lead program, (Z)-Endoxifen, including potential breast cancer indications and anticipated milestones, while specifying that the materials are not deemed filed with the SEC for liability purposes. The company cautioned that these plans are subject to significant risks and uncertainties, citing factors such as the unpredictability of preclinical and clinical results, timing and likelihood of regulatory approvals, macroeconomic conditions, capital-raising needs, and the firm’s ability to remain in compliance with Nasdaq listing standards and protect its intellectual property.

The most recent analyst rating on (ATOS) stock is a Hold with a $0.64 price target. To see the full list of analyst forecasts on Atossa Therapeutics stock, see the ATOS Stock Forecast page.

Atossa Wins FDA Clearance to Advance (Z)-Endoxifen Trial

On January 6, 2026, Atossa Therapeutics announced that the U.S. Food and Drug Administration issued a “Study May Proceed” letter for the company’s investigational new drug application to study its lead candidate (Z)-Endoxifen in metastatic ER+/HER2- breast cancer. The regulatory clearance marks a key milestone that allows Atossa to advance clinical investigation of (Z)-Endoxifen, which has shown a favorable safety profile and distinct pharmacology from tamoxifen, and may offer a treatment option for tumors resistant to other endocrine therapies, potentially strengthening the company’s position in the oncology pipeline and enhancing the strategic value of its intellectual property around (Z)-Endoxifen.

The most recent analyst rating on (ATOS) stock is a Hold with a $0.64 price target. To see the full list of analyst forecasts on Atossa Therapeutics stock, see the ATOS Stock Forecast page.

Atossa Completes FDA Meeting on Regulatory Strategies

On December 4, 2025, Atossa Therapeutics announced the completion of a Type C meeting with the FDA on November 17, 2025, to discuss regulatory strategies for advancing (Z)-endoxifen. The FDA provided feedback on potential expedited pathways for metastatic, neoadjuvant, and risk-reduction breast cancer settings, which Atossa believes will help accelerate its clinical development and regulatory review processes. This meeting marks a significant milestone for Atossa’s programs, as it aims to shorten regulatory timelines and enhance its development strategy across multiple breast cancer indications.

The most recent analyst rating on (ATOS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Atossa Therapeutics stock, see the ATOS Stock Forecast page.